Publications by authors named "F Courtier"
In chronic lymphocytic leukemia (CLL), an elevated glycosyltransferase UGT2B17 expression (UGT2B17) identifies a subgroup of patients with shorter survival and poor drug response. We uncovered a mechanism, possibly independent of its enzymatic function, characterized by an enhanced expression and signaling of the proximal effectors of the pro-survival B cell receptor (BCR) pathway and elevated Bruton tyrosine kinase (BTK) phosphorylation in B-CLL cells from UGT2B17 patients. A prominent feature of B-CLL cells is the strong correlation of UGT2B17 expression with the adverse marker ZAP70 encoding a tyrosine kinase that promotes B-CLL cell survival.
View Article and Find Full Text PDFHormone therapy (HT) is an effective treatment for metastatic endometrial carcinoma (mEC), with limited toxicity and low cost. We focused on molecular analysis of mECs treated by HT and, for the first time to date, we compared the genomic profiles of paired metastasis and primary ECs. The main objective was to identify predictive factors of the response to HT as well as specific altered signaling pathways driving mEC biology.
View Article and Find Full Text PDFArticle Synopsis
- - Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia (ET) are chronic conditions that can evolve into leukemia, although this progression is rare and has a poor prognosis.
- - A study involving 49 cases of leukemic transformations in PV and ET identified three distinct molecular groups that correlate with different timelines for transformation based on specific genetic mutations.
- - The research revealed that some mutations were present during the chronic phase of the disease, but not all mutations were detectable before the onset of leukemia, indicating that the transformation process may involve varying molecular mechanisms over time.
Targeted next-generation sequencing (tNGS) and ex vivo drug sensitivity/resistance profiling (DSRP) have laid foundations defining the functional genomic landscape of acute myeloid leukemia (AML) and premises of personalized medicine to guide treatment options for patients with aggressive and/or chemorefractory hematological malignancies. Here, we have assessed the feasibility of a tailored treatment strategy (TTS) guided by systematic parallel ex vivo DSRP and tNGS for patients with relapsed/refractory AML (number NCT02619071). A TTS issued by an institutional personalized committee could be achieved for 47/55 included patients (85%), 5 based on tNGS only, 6 on DSRP only, while 36 could be proposed on the basis of both, yielding more options and a better rationale.
View Article and Find Full Text PDFArticle Synopsis
- Myelofibrosis (MF) can be primary (PMF) or secondary (SMF) and is associated with a higher risk of acute myeloid leukemia (AML) and shorter life expectancy.
- A study using next generation sequencing found that PMF has more ASXL1 and SRSF2 mutations compared to SMF, with specific mutations indicating poorer survival rates in both forms.
- PMF and SMF show distinct molecular profiles influencing their prognosis, suggesting that integrating genetic mutations with existing scoring systems could enhance patient outcome assessments.